La vendita allo scoperto per BioAtla dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BioAtla. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BioAtla (NASDAQ:BCAB) Azioni, Report sulle vendite allo scoperto

BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

BioAtla Inc

Oppenheimer analyst Chris Kotowski maintains Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) with a Outperform and raises the price target from $91 to $107.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Citigroup, Raises Price Target to $107

WIIM

Celestica shares are trading higher after Barclays initiated coverage on the stock with an Overweight rating and announced a price target of $91.

CIGI

Colliers International Group shares are trading lower after the company reported worse-than-expected Q3 financial results.

RBC Capital analyst Matthew Hedberg reiterates Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) with a Sector Perform and maintains $32 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Teradata, Maintains $32 Price Target

Oppenheimer analyst Chris Kotowski maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Outperform and raises the price target from $50 to $56.

Oppenheimer Maintains Outperform on Bank of America, Raises Price Target to $56

LGIH

LGI Homes shares are trading higher after the company reported better-than-expected Q3 financial results.

Trading Ideas

Moody's Says "Estimate Boeing's Free Cash Flow Will Be Around Negative $(5 Billion) In 2025 And Will Be Only Modestly Positive In 2026"

RBC Capital analyst Brad Heffern maintains UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) with a Sector Perform and lowers the price target from $46 to $45.

RBC Capital Maintains Sector Perform on UDR, Lowers Price Target to $45

As blockchain technology gains traction in traditional finance, Anthony Rousseau, TradeStation's vice president and head of brokerage solutions, shared his thoughts on the complexities of merging these systems. In a pre-event interview for the upcoming <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets conference</a>, Rousseau detailed the careful process of integrating blockchain within long-established financial structures.
<h3 class="wp-block-heading">A Careful Transition for Traditional Institutions</h3>
Rousseau, who previously worked with State Street's digital assets strategy team, described how traditional financial institutions are cautious in their approach to blockchain. 
"Large financial institutions prioritize identifying and mitigating threats to their current structures while adapting new industries to fit within existing regulatory frameworks," he explained. He noted that the demand for regulated digital asset options among retail investors has grown, signaling a shift toward blockchain adoption.
<figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/04195223/905735A6-57D3-4874-9AA1-75D037842DB3-1-7.gif" alt="" class="wp-image-629106" /></a></figure>
<h3 class="wp-block-heading">The Challenges of Compliance and Compatibility</h3>
Incorporating decentralized technology within conventional finance poses challenges, particularly around regulatory compliance and internal risk systems. 
"Significant challenges remain, including ensuring regulatory compliance and integrating decentralized elements with established risk and reporting systems," Rousseau remarked.
The structure of traditional finance, refined over decades, depends heavily on operational consistency, which makes the shift to transparency and decentralized control an intricate process.
<h3 class="wp-block-heading">Looking Toward the Future</h3>
Rousseau noted that this transformation will not happen overnight. 
"Traditional finance&#8230; has spent decades building business models around the inefficiencies of current structures," he said.
A true shift toward a model of individual ownership, supported by blockchain, "will likely take decades to take shape." While slow, he acknowledged that this evolution could lead to lasting changes in the industry.
As the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets event</a> approaches, Rousseau's perspective brings a thoughtful angle to the ongoing discussion of blockchain's role in reshaping finance while preserving structural integrity.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field.&nbsp;<a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a>&nbsp;event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

Will Blockchain's Move Into Finance 'Take Decades To Take Shape'?

RBC Capital analyst Ken Herbert reiterates V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) with a Outperform and maintains $70 price target.

RBC Capital Reiterates Outperform on V2X, Maintains $70 Price Target

ANDE

Andersons shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Intrepid Potash shares are trading higher after the company reported better-than-expected Q3 financial results.

Earnings

PLMR

CORRECTION: Palomar Hldgs Q3 2024 Adj. EPS $1.23 Beats $1.03 Estimate, Net Earned Premiums $135.646M

NMRA

Neumora Therapeutics shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and cut its price target from $18 to $15.

PRIM

Primoris Services shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates.

GLRE

Greenlight Capital Re shares are trading higher after the company reported better-than-expected Q3 financial results.

Piper Sandler analyst Jessica Tassan reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $392 to $394.

Piper Sandler Reiterates Overweight on Cigna, Raises Price Target to $394

SGMO

Sangamo Therapeutics shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $5 to $10.

AGCO Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) shares slipped after the company reported worse-than-expected third-quarter results and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41741857/agco-reports-third-quarter-results" rel="noreferrer noopener">lowered its 2024 outlook.</a>
AGCO reported a third-quarter net sales decline of 24.8% year over year to $2.599 billion, missing the consensus of $2.90 billion.
Regional Sales: South America -47% YoY, Europe/Middle East -18.2% YoY, North America -21.8% YoY, and Asia/Pacific/Africa -11.7% YoY.
Adjusted operating income slid 67% year over year to $143.8 million, and the margin contracted by 710 bps to 5.5%. The gross profit declined 35.4% year-over-year to $603.1 million, and the margin declined 383 bps to 23.2%.
The company reported regional operating margin performance with EME at 6.4%, North America at 7.2%, South America at 11.8%, and APA at 3.8%.
Adjusted EPS of $0.68, down from $3.97 a year ago, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missing the consensus of $1.08.</a>
AGCO&#8217;s cash used in operating activities for the nine months ended September was $108 million, down from cash provided of $202.7 million a year ago. As of September 30, cash and equivalents stood at $642.6 million.
&#8220;We continue to execute against our Farmer-First strategy focused on enhancing profitability through the cycle with our three high-margin initiatives, recent portfolio moves and aggressive actions to control expenses including our ongoing restructuring program,&#8221; said Eric&nbsp;Hansotia, AGCO&#8217;s Chairman, President and Chief Executive Officer.
&#8220;The reaffirmation of our full-year adjusted operating margin&nbsp;outlook&nbsp;of&nbsp;9%&nbsp;underscores this transformation, especially considering the significant market downturn in the&nbsp;third quarter. Low commodity prices and high input costs led to increased conservatism from our dealers and farmers resulting in ongoing production cuts to help reduce AGCO and dealer inventories.&#8221;
The company&#8217;s regular quarterly dividend of $0.29 per common share will be paid on December 16 to all stockholders of <a href="https://www.benzinga.com//node/41528553">record as of the close of business on November 15.</a>
2024 Outlook, lowered: The agricultural machinery maker now expects net sales of $12 billion (prior $12.5 billion) versus the $12.445 billion consensus, <a href="https://www.benzinga.com/calendars/guidance">reflecting lower sales volumes.</a>
AGCO now expects adjusted EPS of ~$7.50 (prior $8.00) versus the consensus of $7.93. The company reaffirms its adjusted&nbsp;operating margin expectation of ~9%.
Price Action: AGCO shares are trading lower by 10.4% at $87.66 at the last check Tuesday.

Equities

Guidance

Movers

AGCO

AGCO Shares Drop As Q3 Results Miss Expectations, 2024 Outlook Cut Amid Softened Global Demand

HighPeak Energy shares are trading higher after the company reported better-than-expected Q3 financial results.

BioAtla GAAP EPS of -$0.44 in-line

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

BioAtla (BCAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Secur...

Reni Benjamin's Buy Rating for BioAtla: Strong Pipeline and Financial Health Signal Upside Potential

Michael Burry's Scion Asset sheds Safe Bulkers, adds Hudson Pacific, others in Q2

Justin Zelin, an analyst from BTIG, reiterated the Buy rating on BioAtla (BCAB – Research Report). The associated price target was raised to $13.00...

Buy Rating for BioAtla: Promising Pipeline and Strategic Partnerships Fuel Optimistic Outlook

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $5.00. Reni Benj...

Buy Rating Affirmed for BioAtla on Strong Clinical Data and Solid Financial Positioning

BioAtla out-licenses BA3362 to Context Therapeutics

Analyst Justin Zelin of BTIG maintained a Buy rating on BioAtla (BCAB – Research Report), retaining the price target of $13.00. Justin Zelin has gi...

Buy Rating Affirmed for BioAtla Amidst Strategic Collaborations and Promising Clinical Catalysts

BioAtla: Numerous Catalysts Coming In Q4

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

BABA

BCAB

BIDU

CNTX

OLPX

PHYS

REAL

SBLK

Health Care

Press Releases

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

Comments

BioAtla

Vendite allo scoperto

BioAtla (NASDAQ:BCAB) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO